1374639-75-4CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1.O=C(O)CCC(=O)ONHANOMFABJQAAH-UHFFFAOYSA-NRibociclib Succinate is the succinate salt form of ribociclib, an orally available inhibitor of the cyclin-dependent kinases (CDKs) 4 and 6, with antineoplastic activity. Upon oral administration, ribociclib specifically targets, binds to and inhibits CDK4 and CDK6. This inhibits the cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, which inhibits phosphorylation of the retinoblastoma (Rb) protein. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of CDK4/6, as seen in certain types of cancer, causes cell cycle dysregulation.
FDA approved drugs -> Active ingredient
EMA approved medicines: Human medicine
FDA approved drugs -> Active ingredient
안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.
Danger
H301 (50%): Toxic if swallowed [Danger Acute toxicity, oral]
P203, P260, P264, P264+P265, P270, P273, P280, P301+P316, P302+P352, P305+P351+P338, P318, P319, P321, P330, P332+P317, P337+P317, P362+P364, P391, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 2 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Drug Induced Liver Injury Rank (DILIrank 2.0)
Ribociclib succinate
vMost-DILI-concern
4
Warnings & precautions
DOI:10.1016/j.drudis.2016.02.015
현재 필터 조건에 해당하는 반응 기록이 없습니다.
불러오는 중…
1374639-75-4DTXSID301027923CHEMBL3707266